MiraVista Diagnostics Provides Diagnostic Fungal Infection Testing for Labs Across the Country
MiraVista Diagnostics serves a wide range of organizations that require specialized expertise in serious fungal infections. We work directly with hospital labs, university research labs. And, we also contract with some of the industry’s largest reference labs and CROs (contract research organizations), providing discrete diagnostic testing for serious fungal infections. Direct or in-direct, our clients select MiraVista Diagnostics because they have confidence in the accuracy and sensitivity of our fungal tests.
Labs That Trust Their Fungal Testing to MiraVista Diagnostics
- HOSPITAL LABS
- RESEARCH UNIVERSITY LABS
- LARGE REFERENCE LABS
- CROs (CONTRACT RESEARCH ORGANIZATIONS)
- GOVERNMENT LABS + MUNICIPALITY LABS
Test Report Updates for 2021
In order to maintain good business practices, MiraVista Diagnostics is providing a 90-day notice of pending updates to our referral testing customers. Beginning March 1, 2021 MiraVista Diagnostics will transition to an improved MVista® Histoplasma Antigen Quantitative EIA. The new…
READ MORE →
Are You Underdiagnosing Coccidioidomycosis?
Are You Underdiagnosing Coccidioidomycosis? Capture Additional Cases with Combined Antigen and Antibody Testing. Dear Colleagues, The prevailing method for diagnosis of coccidioidomycosis is serum antibody testing by immunodiffusion (ID) with a sensitivity of 84.2% and specificity of 96.5%, but a…
READ MORE →
Test Report Updates for 2020
In order to maintain good business practices, MiraVista Diagnostics is providing a 90-day notice of pending updates to our test report format to our referral testing customers. Minor changes have been made to the layout, while critical information such as…
READ MORE →
MiraVista COVID-19 Announcement
MiraVista is open and continues to provide critical diagnostic testing despite the impact COVID-19 has had on staffing. The health and welfare of our team is of critical importance. To limit the opportunity of exposure to COVID-19 for our entire…
READ MORE →
MiraVista Diagnostics LLC has formed an Institutional Biosafety Committee (IBC)
In compliance with the National Institutes of Health Office of Science Policy (NIH OSP), MiraVista Diagnostics LLC has formed an Institutional Biosafety Committee (IBC) to review, approve and confirm that the company’s research involving recombinant/synthetic DNA complies with NIH guidelines….
READ MORE →
Characterization of an Uncinocarpus Reesii-expressed Recombinant Tube Precipitin Antigen of Coccidioides Posadasii for Serodiagnosis
Early and accurate diagnosis of coccidioidomycosis, also known as Valley fever, is critical for appropriate disease treatment and management. Current serodiagnosis is based on the detection of patient serum antibodies that react with tube precipitin (TP) and complement fixation (CF)…
READ MORE →
